Jazz Drug Patent Portfolio
Jazz owns 8 orange book drugs protected by 105 US patents with Luvox Cr having the least patent protection, holding only 1 patent. And Xyrem with maximum patent protection, holding 43 patents. Given below is the list of Jazz's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11160795 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | 01 Mar, 2041 | Active |
| US11406623 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | 01 Mar, 2041 | Active |
| US12102619 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | 01 Mar, 2041 | Active |
| US12138233 | Methods of treating idiopathic hypersomnia | 22 Feb, 2041 | Active |
| US12139233 | Electric snowmobile | 22 Feb, 2041 | Active |
| US12324806 | Method of treating SCLC and managing hepatotoxicity | 29 May, 2040 | Active |
| US12433890 | 29 May, 2040 | Active | |
| US12440490 | 29 May, 2040 | Active | |
| US11207292 | Cannabidiol preparations and its uses | 26 Apr, 2039 | Active |
| US11865102 | Cannabidiol preparations and its uses | 26 Apr, 2039 | Active |
| US11426373 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | 19 Sep, 2037 | Active |
| US10918608 | Use of cannabidiol in the treatment of epilepsy | 13 Oct, 2035 | Active |
| US11065209 | Use of cannabidiol in the treatment of epilepsy | 13 Oct, 2035 | Active |
| US11096905 | Use of cannabinoids in the treatment of epilepsy | 13 Oct, 2035 | Active |
| US11400055 | Use of cannabidiol in the treatment of epilepsy | 13 Oct, 2035 | Active |
| US10092525 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10111840 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10137095 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10603288 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10709671 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10709673 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10709674 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10849860 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10966939 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11154516 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11311498 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11357741 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11446258 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11633369 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11701330 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11766411 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11963937 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US12064399 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9949937 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9956183 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9956184 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9956185 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9956186 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10213400 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US10864181 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US11253494 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US8772306 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US9050302 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US9486426 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Sep, 2033 | Active |
| US10213400 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US10864181 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US11253494 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US11986446 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US8772306 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US9050302 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US9486426 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters | 15 Mar, 2033 | Active |
| US10195168 | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders | 11 Jan, 2033 | Active |
| US10675258 | Method of using gamma-hydroxybutyrate compositions for the treatment of disorders | 11 Jan, 2033 | Active |
| US11554102 | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders | 11 Jan, 2033 | Active |
| US8591922 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | 11 Jan, 2033 | Active |
| US8901173 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | 11 Jan, 2033 | Active |
| US9132107 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | 11 Jan, 2033 | Active |
| US10028912 | Method of lyophilizing liposomes | 15 Oct, 2032 | Active |
| US10166184 | Method of lyophilizing liposomes | 15 Oct, 2032 | Active |
| US10835492 | Method of lyophilizing liposomes | 15 Oct, 2032 | Active |
| US11085043 | Euglobulin-based method for determining the biological activity of defibrotide | 22 Jun, 2032 | Active |
| US11236328 | Euglobulin-based method for determining the biological activity of defibrotide | 22 Jun, 2032 | Active |
| US11746348 | Euglobulin-based method for determining the biological activity of defibrotide | 22 Jun, 2032 | Active |
| US7763615 | Ecteinascidin analogs for use as antitumour agents | 13 Dec, 2029 | Active |
| US8092828 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders | 01 Apr, 2029 | Active |
| US8022279 | Liposomal formulations of anthracycline agents and cytidine analogs | 14 Sep, 2027 | Active |
| US7850990 | Compositions for delivery of drug combinations | 23 Jan, 2027 | Active |
| US9271931 | Compositions for delivery of drug combinations | 23 Jan, 2027 | Active |
| US8518437 | Lipid carrier compositions with enhanced blood stability | 07 Jun, 2026 | Active |
| US8431806 | Liposomal formulations of anthracycline agents and cytidine analogs | 22 Apr, 2025 | Expired |
| US7668730 | Sensitive drug distribution system and method | 16 Dec, 2024 | Expired |
| US7765106 | Sensitive drug distribution system and method | 16 Dec, 2024 | Expired |
| US7765107 | Sensitive drug distribution system and method | 16 Dec, 2024 | Expired |
| US7668730 | Sensitive drug distribution system and method | 16 Jun, 2024 | Expired |
| US7765106 | Sensitive drug distribution system and method | 16 Jun, 2024 | Expired |
| US7765107 | Sensitive drug distribution system and method | 16 Jun, 2024 | Expired |
| US7895059 | Sensitive drug distribution system and method | 17 Jun, 2023 | Expired |
| US8457988 | Sensitive drug distribution system and method | 17 Jun, 2023 | Expired |
| US8589182 | Sensitive drug distribution system and method | 17 Jun, 2023 | Expired |
| US8731963 | Sensitive drug distribution system and method | 17 Jun, 2023 | Expired |
| US7895059 | Sensitive drug distribution system and method | 17 Dec, 2022 | Expired |
| US8457988 | Sensitive drug distribution system and method | 17 Dec, 2022 | Expired |
| US8589182 | Sensitive drug distribution system and method | 17 Dec, 2022 | Expired |
| US8731963 | Sensitive drug distribution system and method | 17 Dec, 2022 | Expired |
| US10195159 | Processes and apparatus for extraction of active substances and enriched extracts from natural products | 07 May, 2022 | Expired |
| US6780889 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 04 Jan, 2021 | Expired |
| US7262219 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 04 Jan, 2021 | Expired |
| US6780889 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 04 Jul, 2020 | Expired |
| US7262219 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 04 Jul, 2020 | Expired |
| US7851506 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Jun, 2020 | Expired |
| US8263650 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Jun, 2020 | Expired |
| US8324275 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Jun, 2020 | Expired |
| US8859619 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Jun, 2020 | Expired |
| US8952062 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Jun, 2020 | Expired |
| US9539330 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Jun, 2020 | Expired |
| US7465462 | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | 10 May, 2020 | Expired |
| US7851506 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Dec, 2019 | Expired |
| US8263650 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Dec, 2019 | Expired |
| US8324275 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Dec, 2019 | Expired |
| US8859619 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Dec, 2019 | Expired |
| US8952062 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Dec, 2019 | Expired |
| US9539330 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | 22 Dec, 2019 | Expired |
| US6024981 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
| US6221392 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
| US6106861 | Multiparticulate tablet disintegrating in less than 40 seconds in the mouth | 05 Dec, 2017 | Expired |
Latest Legal Activities on Jazz's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Jazz.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US10918608 |
|
Email Notification
Critical
| 21 Jun, 2024 | US9956184 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US11096905 |
|
Email Notification
Critical
| 21 Jun, 2024 | US10709673 |
|
Email Notification
Critical
| 21 Jun, 2024 | US10092525 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US10092525 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US11406623 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US9956184 |
|
Email Notification
Critical
| 21 Jun, 2024 | US11406623 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US10709673 |
|
Email Notification
Critical
| 21 Jun, 2024 | US11096905 |
|
Email Notification
Critical
| 18 Jun, 2024 | US9956185 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 18 Jun, 2024 | US9956185 |
|
Email Notification
Critical
| 17 Jun, 2024 | US11865102 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 17 Jun, 2024 | US11865102 |
Jazz's Drug Patent Litigations
Jazz's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 20, 2008, against patent number US7668730. The petitioner , challenged the validity of this patent, with Dayton T. Reardan et al as the respondent. Click below to track the latest information on how companies are challenging Jazz's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8731963 | September, 2015 |
Final Written Decision
(22 Mar, 2017)
| Jazz Pharmaceuticals, Inc. | Par Pharmaceutical, Inc. et al. |
| US7765106 | August, 2015 |
Final Written Decision
(03 Jan, 2017)
| Jazz Pharmaceuticals, Inc. | Wockhardt Bio AG et al. |
| US8772306 | February, 2016 |
Institution Denied
(28 Jul, 2016)
| Jazz Pharmaceutical, Inc. | Amneal Pharmaceuticals LLC |
| US8772306 | February, 2016 |
Terminated-Denied
(28 Jul, 2016)
| Jazz Pharmaceutical, Inc. | Amneal Pharmaceuticals LLC |
| US7668730 | January, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | PAR PHARMACEUTICAL, INC. et al. |
| US8457988 | January, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | PAR PHARMACEUTICAL, INC. |
| US7668730 | August, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Wockhardt Bio AG et al. |
| US7895059 | January, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | PAR PHARMACEUTICAL, INC. |
| US8589182 | August, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Wockhardt Bio AG et al. |
| US7765107 | January, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals LLC et al. |
| US7765107 | August, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Wockhardt Bio AG et al. |
| US8457988 | August, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Wockhardt Bio AG et al. |
| US7895059 | August, 2015 |
FWD Entered
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals LLC |
| US8457988 | August, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals LLC |
| US7895059 | August, 2015 |
FWD Entered
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Wockhardt Bio AG |
| US7895059 | August, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Wockhardt Bio AG et al. |
| US8589182 | January, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals LLC et al. |
| US7765106 | January, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals LLC et al. |
| US8457988 | August, 2015 |
FWD Entered
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals LLC |
| US8589182 | January, 2015 |
FWD Entered
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals LLC |
| US8457988 | August, 2015 |
FWD Entered
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Wockhardt Bio AG |
| US7895059 | August, 2015 |
Final Written Decision
(27 Jul, 2016)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals LLC |
| US8772306 | October, 2015 |
Terminated-Settled
(23 May, 2016)
| Jazz Pharmaceutical, Inc. | Ranbaxy, Inc. |
| US9050302 | March, 2016 |
Terminated-Denied
(23 May, 2016)
| Jazz Pharmaceuticals Ireland Limited | RANBAXY INC |
| US9050302 | March, 2016 |
Institution Denied
(23 May, 2016)
| Jazz Pharmaceuticals Ireland Limited | RANBAXY INC |
| US8772306 | October, 2015 |
Institution Denied
(12 Apr, 2016)
| Jazz Pharmaceutical, Inc. | Par Pharmaceutical, Inc. |
| US8772306 | October, 2015 |
Terminated-Denied
(12 Apr, 2016)
| Jazz Pharmaceutical, Inc. | Par Pharmaceutical, Inc. |
| US7895059 | April, 2015 |
Terminated-Denied
(15 Oct, 2015)
| Jazz Pharmaceuticals, Inc. | Coalition for Affordable Drugs III LLC |
| US7895059 | April, 2015 |
Institution Denied
(15 Oct, 2015)
| Jazz Pharmaceuticals, Inc. | Coalition for Affordable Drugs III LLC |
| US9271931 | October, 2012 |
Decision
(31 Aug, 2015)
| Paul Tardi et al | |
| US7765107 | August, 2014 |
Terminated-Denied
(09 Feb, 2015)
| Jazz Pharmaceuticals Inc. | Roxane Laboratories, Inc. |
| US7765107 | August, 2014 |
Institution Denied
(09 Feb, 2015)
| Jazz Pharmaceuticals Inc. | Roxane Laboratories, Inc. et al. |
| US7765106 | August, 2014 |
Terminated-Denied
(09 Feb, 2015)
| Jazz Pharmaceuticals, Inc. | Roxane Laboratories, Inc. |
| US7765106 | August, 2014 |
Institution Denied
(09 Feb, 2015)
| Jazz Pharmaceuticals, Inc. | Roxane Laboratories, Inc. et al. |
| US8457988 | July, 2014 |
Institution Denied
(13 Jan, 2015)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC et al. |
| US8457988 | July, 2014 |
Terminated-Denied
(13 Jan, 2015)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
| US8589182 | July, 2014 |
Terminated-Denied
(13 Jan, 2015)
| Jazz Pharmaceuticals, Inc. | PAR PHARMACEUTICAL, INC. |
| US7668730 | July, 2014 |
Terminated-Denied
(13 Jan, 2015)
| Jazz Pharmaceuticals, Inc. | PAR PHARMACEUTICAL, INC. |
| US7668730 | July, 2014 |
Institution Denied
(13 Jan, 2015)
| Jazz Pharmaceuticals, Inc. | PAR PHARMACEUTICAL, INC. et al. |
| US8589182 | July, 2014 |
Institution Denied
(13 Jan, 2015)
| Jazz Pharmaceuticals, Inc. | PAR PHARMACEUTICAL, INC. et al. |
| US7895059 | June, 2014 |
Institution Denied
(13 Jan, 2015)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC et al. |
| US7895059 | June, 2014 |
Terminated-Denied
(13 Jan, 2015)
| Jazz Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
| US8518437 | December, 2010 |
Decision
(05 Mar, 2013)
| Paul Tardi et al | |
| US7668730 | May, 2008 |
Decision
(31 Aug, 2009)
| Dayton T. Reardan et al | |
Jazz Drug Patents' Oppositions Filed in EPO
Jazz drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 23, 2018, by Hoffmann Eitle. This opposition was filed on patent number EP14709858A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17200498A | Oct, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP17200498A | Oct, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP17200498A | Oct, 2022 | SANDOZ AG | Granted and Under Opposition |
| EP15784111A | Apr, 2021 | James Poole Limited | Granted and Under Opposition |
| EP17200764A | Sep, 2020 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP17200764A | Sep, 2020 | Hexal AG | Granted and Under Opposition |
| EP17200764A | Sep, 2020 | Zentiva, k.s. | Granted and Under Opposition |
| EP12841616A | Apr, 2020 | D Young & Co LLP | Granted and Under Opposition |
| EP12841616A | Apr, 2020 | SANDOZ AG | Granted and Under Opposition |
| EP17200764A | Mar, 2020 | Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Granted and Under Opposition |
| EP12756826A | Aug, 2018 | Aechter, Bernd | Patent maintained as amended |
| EP08730048A | Aug, 2018 | Generics (U.K.) Limited | Revoked |
| EP08730048A | Aug, 2018 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP14709858A | Aug, 2018 | Hexal AG | Revoked |
| EP14709858A | Aug, 2018 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Revoked |
| EP14709858A | Jul, 2018 | Hoffmann Eitle | Revoked |
Jazz's Family Patents
Jazz drugs have patent protection in a total of 35 countries. It's US patent count contributes only to 27.9% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Jazz Drug List
Given below is the complete list of Jazz's drugs and the patents protecting them.
1. Defitelio
Defitelio is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11085043 | Euglobulin-based method for determining the biological activity of defibrotide |
22 Jun, 2032
(6 years from now)
| Active |
| US11236328 | Euglobulin-based method for determining the biological activity of defibrotide |
22 Jun, 2032
(6 years from now)
| Active |
| US11746348 | Euglobulin-based method for determining the biological activity of defibrotide |
22 Jun, 2032
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Defitelio's drug page
2. Epidiolex
Epidiolex is protected by 33 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11160795 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
01 Mar, 2041
(15 years from now)
| Active |
| US11406623 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
01 Mar, 2041
(15 years from now)
| Active |
| US12102619 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
01 Mar, 2041
(15 years from now)
| Active |
| US11207292 | Cannabidiol preparations and its uses |
26 Apr, 2039
(13 years from now)
| Active |
| US11865102 | Cannabidiol preparations and its uses |
26 Apr, 2039
(13 years from now)
| Active |
| US10918608 | Use of cannabidiol in the treatment of epilepsy |
13 Oct, 2035
(9 years from now)
| Active |
| US11065209 | Use of cannabidiol in the treatment of epilepsy |
13 Oct, 2035
(9 years from now)
| Active |
| US11096905 | Use of cannabinoids in the treatment of epilepsy |
13 Oct, 2035
(9 years from now)
| Active |
| US11400055 | Use of cannabidiol in the treatment of epilepsy |
13 Oct, 2035
(9 years from now)
| Active |
| US10092525 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US10111840 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US10137095 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US10603288 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US10709671 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US10709673 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US10709674 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US10849860 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US10966939 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US11154516 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US11311498 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US11357741 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US11446258 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US11633369 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US11701330 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US11766411 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US11963937 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US12064399 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US9949937 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US9956183 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US9956184 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US9956185 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US9956186 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(9 years from now)
| Active |
| US10195159 | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
07 May, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epidiolex's drug page
3. Fazaclo Odt
Fazaclo Odt is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6024981 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(7 years ago)
| Expired |
| US6221392 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(7 years ago)
| Expired |
| US6106861 | Multiparticulate tablet disintegrating in less than 40 seconds in the mouth |
05 Dec, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fazaclo Odt's drug page
4. Luvox Cr
Luvox Cr is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7465462 | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
10 May, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Luvox Cr's drug page
5. Vyxeos
Vyxeos is protected by 9 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10028912 | Method of lyophilizing liposomes |
15 Oct, 2032
(6 years from now)
| Active |
| US10166184 | Method of lyophilizing liposomes |
15 Oct, 2032
(6 years from now)
| Active |
| US10835492 | Method of lyophilizing liposomes |
15 Oct, 2032
(6 years from now)
| Active |
| US8092828 | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
01 Apr, 2029
(3 years from now)
| Active |
| US8022279 | Liposomal formulations of anthracycline agents and cytidine analogs |
14 Sep, 2027
(1 year, 8 months from now)
| Active |
| US7850990 | Compositions for delivery of drug combinations |
23 Jan, 2027
(1 year, 13 days from now)
| Active |
| US9271931 | Compositions for delivery of drug combinations |
23 Jan, 2027
(1 year, 13 days from now)
| Active |
| US8518437 | Lipid carrier compositions with enhanced blood stability |
07 Jun, 2026
(4 months from now)
| Active |
| US8431806 | Liposomal formulations of anthracycline agents and cytidine analogs |
22 Apr, 2025
(8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyxeos's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Xyrem
Xyrem is protected by 43 patents, out of which 30 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10213400
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US10864181
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US11253494
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US8772306
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US9050302
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US9486426
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US10213400 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US10864181 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US11253494 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US11986446 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US8772306 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US9050302 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US9486426 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US7668730
(Pediatric)
| Sensitive drug distribution system and method |
16 Dec, 2024
(1 year, 24 days ago)
| Expired |
| US7765106
(Pediatric)
| Sensitive drug distribution system and method |
16 Dec, 2024
(1 year, 24 days ago)
| Expired |
| US7765107
(Pediatric)
| Sensitive drug distribution system and method |
16 Dec, 2024
(1 year, 24 days ago)
| Expired |
| US7668730 | Sensitive drug distribution system and method |
16 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US7765106 | Sensitive drug distribution system and method |
16 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US7765107 | Sensitive drug distribution system and method |
16 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US7895059
(Pediatric)
| Sensitive drug distribution system and method |
17 Jun, 2023
(2 years ago)
| Expired |
| US8457988
(Pediatric)
| Sensitive drug distribution system and method |
17 Jun, 2023
(2 years ago)
| Expired |
| US8589182
(Pediatric)
| Sensitive drug distribution system and method |
17 Jun, 2023
(2 years ago)
| Expired |
| US8731963
(Pediatric)
| Sensitive drug distribution system and method |
17 Jun, 2023
(2 years ago)
| Expired |
| US7895059 | Sensitive drug distribution system and method |
17 Dec, 2022
(3 years ago)
| Expired |
| US8457988 | Sensitive drug distribution system and method |
17 Dec, 2022
(3 years ago)
| Expired |
| US8589182 | Sensitive drug distribution system and method |
17 Dec, 2022
(3 years ago)
| Expired |
| US8731963 | Sensitive drug distribution system and method |
17 Dec, 2022
(3 years ago)
| Expired |
| US6780889
(Pediatric)
| Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
04 Jan, 2021
(5 years ago)
| Expired |
| US7262219
(Pediatric)
| Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
04 Jan, 2021
(5 years ago)
| Expired |
| US6780889 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
04 Jul, 2020
(5 years ago)
| Expired |
| US7262219 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
04 Jul, 2020
(5 years ago)
| Expired |
| US7851506
(Pediatric)
| Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Jun, 2020
(5 years ago)
| Expired |
| US8263650
(Pediatric)
| Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Jun, 2020
(5 years ago)
| Expired |
| US8324275
(Pediatric)
| Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Jun, 2020
(5 years ago)
| Expired |
| US8859619
(Pediatric)
| Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Jun, 2020
(5 years ago)
| Expired |
| US8952062
(Pediatric)
| Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Jun, 2020
(5 years ago)
| Expired |
| US9539330
(Pediatric)
| Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Jun, 2020
(5 years ago)
| Expired |
| US7851506 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Dec, 2019
(6 years ago)
| Expired |
| US8263650 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Dec, 2019
(6 years ago)
| Expired |
| US8324275 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Dec, 2019
(6 years ago)
| Expired |
| US8859619 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Dec, 2019
(6 years ago)
| Expired |
| US8952062 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Dec, 2019
(6 years ago)
| Expired |
| US9539330 | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
22 Dec, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xyrem's drug page
7. Xywav
Xywav is protected by 24 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12138233 | Methods of treating idiopathic hypersomnia |
22 Feb, 2041
(15 years from now)
| Active |
| US12139233 | Electric snowmobile |
22 Feb, 2041
(15 years from now)
| Active |
| US11426373 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
19 Sep, 2037
(11 years from now)
| Active |
| US10213400
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US10864181
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US11253494
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US8772306
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US9050302
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US9486426
(Pediatric)
| Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Sep, 2033
(7 years from now)
| Active |
| US10213400 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US10864181 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US11253494 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US11986446 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US8772306 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US9050302 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US9486426 | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
15 Mar, 2033
(7 years from now)
| Active |
| US10195168 | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
11 Jan, 2033
(7 years from now)
| Active |
| US10675258 | Method of using gamma-hydroxybutyrate compositions for the treatment of disorders |
11 Jan, 2033
(7 years from now)
| Active |
| US11554102 | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
11 Jan, 2033
(7 years from now)
| Active |
| US8591922 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
11 Jan, 2033
(7 years from now)
| Active |
| US8901173 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
11 Jan, 2033
(7 years from now)
| Active |
| US9132107 | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
11 Jan, 2033
(7 years from now)
| Active |
| US8731963
(Pediatric)
| Sensitive drug distribution system and method |
17 Jun, 2023
(2 years ago)
| Expired |
| US8731963 | Sensitive drug distribution system and method |
17 Dec, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xywav's drug page
8. Zepzelca
Zepzelca is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12324806 | Method of treating SCLC and managing hepatotoxicity |
29 May, 2040
(14 years from now)
| Active |
| US12433890 |
29 May, 2040
(14 years from now)
| Active | |
| US12440490 |
29 May, 2040
(14 years from now)
| Active | |
| US7763615 | Ecteinascidin analogs for use as antitumour agents |
13 Dec, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepzelca's drug page